Prosecution Insights
Last updated: November 20, 2026

Constantina E Stavrou, USPTO Patent Examiner

Listed by the USPTO as STAVROU, CONSTANTINA E

Tech Center 1600 • Art Units: 1632 1678

This examiner grants 42% of resolved cases

Analysis

STAVROU, CONSTANTINA E is assigned to tech center 1600 and art unit 1632. The record includes 93 resolved cases, with an allowance rate of 41.9%. The interview lift is 36.1%, and the median time to allowance is 1428 days. The figures show a limited examination history, a relatively low allowance outcome, and a substantial measured interview association.

Massachusetts Institute of Technology, University Health Network, and The Brigham and Women's Hospital Inc. are the leading companies or institutions listed. The firms are Johnson, Marcou, Isaacs & Nix, LLC, WC&F IP, and Xsensus. Practitioners may prioritize interviews that explain the technical contribution, while preparing detailed written distinctions and multiple amendment routes for the extended prosecution timeline.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

41.9%
Allow Rate
-18.1% vs TC avg
175
Total Applications
+36.1%
Interview Lift
1428
Avg Prosecution Days
Based on 93 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
20.5%
§102 Novelty
43.1%
§103 Obviousness
30.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18572723 ADENO-ASSOCIATED VIRAL (AAV) VECTORS FOR TISSUE-TARGETED EXPRESSION OF THERAPEUTIC GENES Non-Final OA The Brigham and Women's Hospital, Inc.
18288345 VIRAL VECTOR PRODUCTION SYSTEM Non-Final OA Novartis AG
18042040 PROCESS SYSTEM FOR BIOREACTOR-BASED CLEAN MEAT PRODUCTION Final Rejection Merck Patent GmbH
18701358 RNA-GUIDED TRANS-SPLICING OF RNA Non-Final OA MASSACHUSETTS INSTITUTE OF TECHNOLOGY
16707681 PRE-SHAPED ALLOGRAFT IMPLANT FOR RECONSTRUCTIVE SURGICAL USE AND METHODS OF MANUFACTURE AND USE Non-Final OA Allosource
19357552 DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS Final Rejection ImmunityBio, Inc.
18685660 METHODS FOR PRODUCTION OF ENGINEERED CELLS Non-Final OA Centre National de la Recherche Scientifique
17545416 METHODS FOR CONTROLLED INDUCTION OF BIOENGINEERED NEUROEPITHELIAL TISSUES AND 3-D NEUROEPITHELIAL TUBES Non-Final OA Wisconsin Alumni Research Foundation
18690594 SALMONELLA ENGINEERED FOR NONTOXIC COLONIZATION OF TUMORS Non-Final OA Regents of the University of Minnesota
17571802 Methods for cryopreservation of sub-millimeter and millimeter scale biological materials Non-Final OA Regents of the University of Minnesota
16632332 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES Non-Final OA THE GENERAL HOSPITAL CORPORATION
17282117 MODULAR BIOFABRICATION PLATFORM FOR DIVERSE TISSUE ENGINEERING APPLICATIONS AND RELATED METHOD THEREOF Non-Final OA University of Virginia Patent Foundation
18252714 ECTOPIC CELLULAR GROWTH FACTOR EXPRESSION FOR LOW-COST PRODUCTION OF CELL-CULTURED FOODS Final Rejection Trustees of Tufts College
16975987 NANOPATTERNING FOR CONTROLLING CELL CYTOSKELETON Non-Final OA NORTHWESTERN UNIVERSITY
18642228 METHODS OF PRODUCING TENDON NEOTISSUE FROM ADULT STEM CELLS AND USES THEREOF Non-Final OA Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
18023289 COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS Final Rejection UNIVERSITY HEALTH NETWORK
17867335 COMPOSITIONS AND METHODS FOR GENERATION OF RETINAL GANGLION CELLS FROM INDUCIBLE PLURIPOTENT STEM CELLS FOR THE TREATMENT OF PROGRESSIVE OPTIC NEUROPATHIES, INCLUDING GLAUCOMA Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
18837739 COMPOSITIONS AND METHODS FOR EXPANDING LYMPHOCYTES Non-Final OA StemCell Technologies Canada Inc.
18559577 METHOD OF MANUFACTURING ALVEOLAR ORGANOID USING ALVEOLAR CELL-DERIVED INDUCED PLURIPOTENT STEM CELLS Final Rejection THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
17600348 CELL CONSTRUCT AND CELL CONSTRUCT PRODUCTION METHOD Final Rejection Kyoto Prefectural Public University Corporation
18562448 SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS Non-Final OA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Constantina E Stavrou's allowance rate?

41.9% of resolved applications examined by Constantina E Stavrou were allowed (93 resolved cases), compared with 38.0% across Art Unit 1632 over the last five years.

Does an interview help with examiner Constantina E Stavrou?

This examiner's interview lift is +36.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Constantina E Stavrou take to allow a patent?

Applications allowed by Constantina E Stavrou took 1,428 days on average from filing to allowance.

Which art unit does examiner Constantina E Stavrou work in?

Constantina E Stavrou examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month